Abstract:Background: Previous study reveals that, exogenous bone marrow mesenchymal stem cells (MSCs) may settle down in kidney and differentiate into renal cells, as well as participate in the repair of injured renal tissues. However, the repairing pathway is unclear. Objective: To investigate the potential effect of exogenous MSCs transplantation on renal injury. Design, time and setting: An in vivo trial of cytology was performed in the Urinary Surgery Institute of Nanchang University (Nanchang, Jiangxi, China) from March to September in 2007. Materials: Fifty-six SD rats of clean grade were recruited. Eight male rats of them were used to prepare MSCs, while other 48 female rats were divided into three groups at random, namely cell transplantation group, model control group and sham group. Each group contained 16 rats. Fluorochrome DAPI was a product of Biotium Inc. Ricinus communis agglutinin was produced by Vector Laboratories. BrdU was offered by Sigma. Methods: Bone marrow-derived MSCs were collected from male SD rats, then isolated by Percoll density gradient centrifugation and labeled with DAPI at a density of 1.5 × 1010/L. Renal injury models induced by ischemia and reperfusion were created in cell transplantation group and model control, while renal vessels were not ligated in the sham group. SD rats were subjected to clamping renal pedicles for 45 minutes. DAPI-labeled MSCs or 1 mL saline were transplanted into the rats by inferior vena cava in cell transplantation group or model control group and sham group. All animals received daily injection of BrdU, then blood and renal tissues were sampled. Main outcome measures: Immunohistochemical methods and fluorescence microscope were performed to identify transplanted MSCs and BrdU in renal tissues. To confirm if the MSCs may differentiate into renal tubular cells, ricinus communis agglutinin that binds specifically to the luminal surface of tubules was used. Biochemistry methods were used to detect the levels of creatinine and blood urea nitrogen in serum. Results: At day 3 after transplantation, the DAPI-positive cells were few, but obviously increased at day 4 (P < 0.05). Most of DAPI-labeled cells could express ricinus communis agglutinin-positive cells simultaneously and were mainly distributed in the renal tubule. There were few positive cells in renal cortex and kidney inner medullary, even absent in renal glomerulus. In sham group, the renal tissue cells proliferated slowly, and BrdU-positive cells were remarkably lower than that in model control group at day 4 (P < 0.05); BrdU-positive cells were distributed identically with DAPI-positive cells in the cell transplantation and model control groups at days 2, 3 and 4, but the BrdU-positive cells in transplantation group were much more than that of the control group (P < 0.05) Compared with the model control group, the serum level of blood urea nitrogen in cell transplantation group was significantly decreased at days 1 and 2 (P < 0.05), and the serum levels of creatinine were significantly lower at days 1, 2 and 3 (P < 0.05). Conclusion: Exogenous MSCs can migrate and repopulate in the ischemically injured kidney, differentiate into renal tubular cells and promote cells proliferation to repair renal injury. MSCs have depressant effect on increasing degrees of blood urea nitrogen and creatinine at early stage, this protective effect has no association with location and differentiation of MSCs.

[Transplantation of Human Umbilical Cord Mesenchymal Stem Cells Alleviates the Progression of FSGS in Rats].

Transplantation of umbilical cord mesenchymal stem cells into mice with focal segmental glomerulosclerosis delayed disease manifestation.

The preliminarily investigation of therapeutic effects of mesenchymai stem cells on rat fulminant hepatic failure

Human umbilical cord mesenchymal stem cell attenuates renal fibrosis via TGF-β/Smad signaling pathways in vivo and in vitro

Mesenchymal stem cells transplantation attenuates hyperuricemic nephropathy in rats

Transplantation of Human Bone Marrow Mesenchymal Stem Cell Ameliorates the Autoimmune Pathogenesis in MRL/lpr Mice

Transplantation of Umbilical Cord Mesenchymal Stem Cells Alleviates Lupus Nephritis in Mrl/Lpr Mice

Umbilical Cord-Derived Mesenchymal Stem Cells Ameliorate Nephrocyte Injury and Proteinuria in a Diabetic Nephropathy Rat Model

Mesenchymal Stem Cells from the Human Umbilical Cord Ameliorate Fulminant Hepatic Failure and Increase Survival in Mice

Renoprotective effect of human umbilical cord-derived mesenchymal stem cells in immunodeficient mice suffering from acute kidney injury

Mesenchymal Stem Cells Ameliorate Uric Acid Induced Nephropathy in Rats

Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells Against Acute Tubular Necrosis Quantified Through Measures of Inos, BMP-7 and Bcl-2

Hepatocyte Growth Factor Modified Human Umbilical Cord Mesenchymal Stem Cells Accelerate the Recovery of Mouse Hepatic Injury

Umbilical Cord Mesenchymal Stem Cells Ameliorate Kidney Injury in MRL/Ipr Mice Through the TGF-β1 Pathway

The effect of umbilical cord mesenchymal stem cells transplantation for the MRL/Ipr mice

Umbilical Cord Mesenchymal Stem Cell Transplantation Modulated Th17/Treg Balance and Delayed Lupus Progression in MRL/lpr Mice

Exosomes released by human umbilical cord mesenchymal stem cells protect against renal interstitial fibrosis through ROS-mediated P38MAPK/ERK signaling pathway

Bone marrow-derived mesenchymal stem cells attenuate tubulointerstitial injury through multiple mechanisms in UUO model.

Enhanced renoprotective effect of GDNF-modified adipose-derived mesenchymal stem cells on renal interstitial fibrosis

Exosomes From Human Umbilical Cord Stem Cells Suppress Macrophage-to-myofibroblast Transition, Alleviating Renal Fibrosis

Bone marrow mesenchymal stem cells transplantation for the repair of renal injury